Inhibikase Therapeutics, Inc. Annual Return On Equity in % from 2020 to 2023

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from 2020 to 2023.
  • Inhibikase Therapeutics, Inc. Return On Equity for the quarter ending June 30, 2024 was -194 %, a 132% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Return On Equity for 2023 was -108 %, a 63.4% decline from 2022.
  • Inhibikase Therapeutics, Inc. annual Return On Equity for 2022 was -65.8 %, a 52.2% decline from 2021.
  • Inhibikase Therapeutics, Inc. annual Return On Equity for 2021 was -43.3 %, a 119% decline from 2020.
Return On Equity, Annual (%)
Return On Equity, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2023 -108 -41.8 -63.4% Jan 1, 2023 Dec 31, 2023
2022 -65.8 -22.6 -52.2% Jan 1, 2022 Dec 31, 2022
2021 -43.3 -277 -119% Jan 1, 2021 Dec 31, 2021
2020 234 Jan 1, 2020 Dec 31, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.